Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SUMMIT THERAPEUTICS INC.

(SMMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Follow Market Higher Wednesday

09/22/2021 | 01:26pm EST


ę MT Newswires 2021
All news about SUMMIT THERAPEUTICS INC.
11/15Summit Therapeutics Q3 Loss per Share Narrows, Revenue Rises
MT
11/15SUMMIT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/15SUMMIT THERAPEUTICS : Reports Financial Results and Operational Progress for the Third Qua..
PU
11/15Earnings Flash (SMMT) SUMMIT THERAPEUTICS Posts Q3 Revenue $1.31M
MT
11/15Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Thir..
AQ
11/10ACURX PHARMACEUTICALS' DRUG CANDIDAT : Acxp)
AQ
11/03Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical..
PU
11/03SUMMIT THERAPEUTICS INC. : Change in Directors or Principal Officers, Other Events, Financ..
AQ
11/03Summit Therapeutics Inc. Appoints Urte Gayko as Board of Director
CI
More news
Analyst Recommendations on SUMMIT THERAPEUTICS INC.
More recommendations
Financials
Sales 2021 0,18 M 0,24 M 0,24 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 369 M 489 M 489 M
Capi. / Sales 2021 2 055x
Capi. / Sales 2022 -
Nbr of Employees 80
Free-Float 26,3%
Chart SUMMIT THERAPEUTICS INC.
Duration : Period :
Summit Therapeutics Inc. Technical Analysis Chart | SMMT | US86627T1088 | MarketScreener
Technical analysis trends SUMMIT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 5,00 
Average target price
Spread / Average Target -
Managers and Directors
Robert William Duggan Executive Chairman, Chief Executive Officer & CFO
David Powell Chief Scientific Officer
Jos Houbiers Chief Medical Officer
Camilla S. Graham Chief Clinical Affairs Officer
Mahkam Zanganeh Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
SUMMIT THERAPEUTICS INC.6.38%489
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819